INFLUENCE OF KINESITHERAPY ON THE CONCENTRATION OF IRISIN IN WOMEN WITH CARDIOVASCULAR SYSTEM DISEASES

The aim of the research.  Clarification  of  the  role  of  irisin  in  the  pathogenesis  of  diseases  of  the cardiovascular system. 

Materials and methods. 41 women aged 32 to 69 years, divided into 2 groups, were studied. The first group consisted of 16 women (49.8 years old (41.0; 59.0)), who did not have pronounced disorders in the activity of the cardiovascular system (control). The second group consisted of 25 patients (mean age 53.4 years (43.0;  62.0))  with  ischemic  heart  disease,  stable  angina  pectoris  I-II  functional  class  and  arterial hypertension grade 2-3. 

Results. Compared with relatively healthy women with a pathology of the cardiovascular system (CVS), the content of irisin was elevated. After a single kinesitherapeutic load in relatively healthy women, the irisin content increased, while in women with CVS damage, it did not change or decrease. In relatively healthy women, both before and after exercise, negative relationships were found between irisin concentration, age, BMI average arterial pressure (ABP) and positive ones with progesterone concentration and dynamometry (after exercise), as well as with heart rate (after exercise). In patients with CVS damage, in contrast to relatively healthy ones, both before and after exercise, no correlation of irisin level with age and ABP is revealed, but in addition to healthy ones, positive correlations with glucose, dynamometry after exercise and negative with the heart rate before the load. 

Conclusion. During exercise in relatively healthy women, the concentration of irisin increases, while in patients  with  cardiovascular  pathology  it  can  either  increase  or  decrease.  The  correlations  found  are consistent with the idea of the appointment of irisin as a fat burner hormone that provides optimal conditions for energy balance during exercise.

1. Reimers C.D., Knapp G., Reimers A.K. Does physical activity increase life expectancy? A review of the literature. Journal of Aging Research. 2012. 9. 243-58. doi: 10.1155/2012/243958.

2. Samitz G., Egger M., Zwahlen M. Domains of physical activity and all-cause mortality. systematic review and dose-response meta-analysis of cohort studies. International journal of epidemiology. 2011. 40. 1382-400. doi: 10.1093/ije/dyr112.

3. Warburton D., Charlesworth S., Ivey A., Nettlefold L., Bredin S. A systematic review of the evidence for Canada's Physical Activity Guidelines for Adults, International Journal of Behavioral Nutrition and Physical Activity. 2010. 7. 7-39. doi: 10.1186/1479-5868-7-39.

4. Gremeaux V., Gayda M., Lepers R., Sosner P., Juneau M., Nigam A. Exercise and longevity. Maturitas. 2012. 73 (4). 312-7. doi: 10.1016/j.maturitas.2012.09.012.

5. Miyakoshi N. Aging and homeostasis. Prevention and treatment of locomotive syndrome. Clin Calcium. 2017. 27 (7). 1013-20. doi: CliCa170710131020.

6. Kettunen J.A., Kujala U.M., Kaprio J., Bäckmand H., Peltonen M., Eriksson J.G., Sarna S. All-cause and disease-specific mortality among male, former elite athletes. an average 50-year follow-up. Br J Sports Med. 2015. 49 (13). 893-7. doi: 10.1136/bjsports-2013-093347.

7. Stepanov A.V., Davydov S.O., Kuznik B.I., Guseva E.S., Smolyakov Y.N. The influence of moderate physical exercise on concentration of junctional adhesion molecules jam-a, estrogen, progesterone, prolactin and lipid metabolism in women with essential hypertension. Zabajkal'skij medicinskij vestnik. 2019. (4). 122-127.

8. Bostrom P., Wu J., Jedrychowski M.P., Korde A., Ye L., Lo J.C., Kajimura S. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012. 481 (7382). 463-8. doi: 10.1038/nature10777.

9. Rana K.S., Arif M., Hill E.J., Aldred S., Nagel D.A., Nevill A., Brown J.E. Plasma irisin levels predict telomere length in healthy adults. Age. 2014. 36 (2). 995-1001. doi: 10.1007/s11357-014-9620-9.

10. Song H., Xu J., Lv N., Zhang Y., Wu F., Li H., Fang X. Irisin reverses platelet derived growth factor-BB-induced vascular smooth muscle cells phenotype modulation through STAT3 signaling pathway. Biochemical and biophysical research communications. 2016. 479 (2). 139-145. doi: 10.1016/j.bbrc.2016.07.052.

11. Jedrychowski M.P., Wrann C.D., Paulo J.A., Gerber K.K., Szpyt J., Robinson M.M., Spiegelman B.M. Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry. Cell metabolism. 2015. 22 (4). 734-40. doi: 10.1016/j.cmet.2015.08.001.

12. Askari H., Rajani S.F., Poorebrahim M., Haghi-Aminjan H., Raeis-Abdollahi E., Abdollahi M. A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis. An introductory review. Pharmacological research. 2018. 129. 44-55. doi: 10.1016/j.phrs.2018.01.012.

13. Emanuele E., Minoretti P., Pareja-Galeano H., Sanchis-Gomar F., Garatachea N., Lucia A. Serum irisin levels, precocious myocardial infarction, and healthy exceptional longevity. The American journal of medicine. 2014. 127 (9). 888-90. doi: 10.1016/j.amjmed.2014.04.025.

14. Icli A., Cure E., Cumhur Cure M., Uslu A.U., Balta S., Arslan S., Sakiz D., Kucuk A. Novel myokine. Irisin may be an independent predictor for subclinic atherosclerosis in Behçet's disease. Journal of Investigative Medicine. 2016. 64 (4). 875-81. doi: 10.1136/jim-2015-000044.

15. Lee M.J., Lee S.A., Nam B.Y., Park S., Lee S.H., Ryu H.J., Park J.T. Irisin, a novel myokine is an independent predictor for sarcopenia and carotid atherosclerosis in dialysis patients // Atherosclerosis. 2015. 242 (2). 476-82. doi: 10.1016/j.atherosclerosis.2015.08.002.

16. Wu H., Guo P., Jin Z., Li X., Yang X., Tang C., Wang Y., Ke J. Serum levels of irisin predict short-term outcomes in ischemic stroke. Cytokine. 2018. 122. 154303. doi: 10.1016/j.cyto.2018.02.017.

17. Aronis K.N., Moreno M., Polyzos S.A., Moreno-Navarrete J.M., Ricart W., Delgado E., Spiro Iii A. Circulating irisin levels and coronary heart disease. association with future acute coronary syndrome and major adverse cardiovascular events. International Journal of Obesity. 2015. 39 (1). 156-61. doi: 10.1038/ijo.2014.101.

18. Yu Q., Kou W., Xu X., Zhou S., Luan P., Xu X., Li H., Zhuang J., Wang J., Zhao Y., Xu Y., Peng W. FNDC5/Irisin inhibits pathological cardiac hypertrophy. Clinical Science. 2019. 133 (5). 611-27. doi: 10.1042/CS20190016.

19. Pardo M., Crujeiras A.B., Amil M. Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int. J. Endocrinol. 2014. doi: 10.1155/2014/857270.

20. Park K.H., Zaichenko L., Peter P., Davis C.R., Crowell J.A., Mantzoros C.S. Diet quality is associated with circulating C-reactive protein but not irisin levels in humans. Metabolism. 2014. 63 (2). 233-41. doi: 10.1016/j.metabol.2013.10.011.

21. Fukushima Y., Kurose S., Shinno H., Thu T., Cao H., Takao N., Kimura Y. Effects of Body Weight Reduction on Serum Irisin and Metabolic Parameters in Obese Subjects. Diabetes & metabolism journal. 2016. 40 (5). 386-95. doi: 10.4093/dmj.2016.40.5.386.

22. Daskalopoulou S.S., Cooke A.B., Yessica-Haydee Y.H., Mutter A.F., Filippaios A., Mesfum E.T., Mantzoros C.S. Plasma irisin levels progressively increase in response to increasing exercise workloads in young, healthy, active subjects. Eur. J. Endocrinol. 2014. 171 (3). 343-52. doi: 10.1530/EJE-14-0204.

23. Norheim F., Langleite T.M., Hjorth M., Holen T., Kielland A., Stadheim H.K., Drevon C.A. The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. The FEBS journal. 2014. 281 (3). 739-49. doi: 10.1111/febs.12619.

24. Tsuchiya Y., Ando D., Takamatsu K., Goto K. Resistance exercise induces a greater irisin response than endurance exercise. Metabolism. 2015. 64 (9). 1042-50. doi: 10.1016/j.metabol.2015.05.010.

25. Czarkowska-Paczek B., Zendzian-Piotrowska M., Gala K., Sobol M., Paczek L. One session of exercise or endurance training does not influence serum levels of irisin in rats. J. Physiol. Pharmacol. 2014. 65 (3). 449-54.

26. Hecksteden A, Wegmann M., Steffen A., Kraushaar J., Morsch A., Ruppenthal S., Meyer T. Irisin and exercise training in humans – Results from a randomized controlled training trial. BMC Medicine. 2013. 11 (1). 235. doi: 10.1186/1741-7015-11-235.

27. Ateş İ., Altay M., Topçuoğlu C., Yılmaz F.M. Circulating levels of irisin is elevated in hypothyroidism, a case-control study. Archives of endocrinology and metabolism. 2016. 60 (2). 95-100. doi: 10.1590/2359-3997000000077.

28. Tanisawa K., Taniguchi H., Sun X., Ito T., Cao Z.B., Sakamoto S., Higuchi M. Common single nucleotide polymorphisms in the FNDC5 gene are associated with glucose metabolism but do not affect serum irisin levels in Japanese men with low fitness levels. Metabolism. 2014. 63 (4). 574-83. doi: 10.1016/j.metabol.2014.01.005.

29. Panagiotou G., Mu L., Na B., Mukamal K.J., Mantzoros C.S. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism. 2014. 63 (10). 1265-71. doi: 10.1016/j.metabol.2014.06.001.

30. Maciorkowska M, Musiałowska D, Małyszko J. Adropin and irisin in arterial hypertension, diabetes mellitus and chronic kidney disease. Advances in clinical and experimental medicine. 2019. 28 (11). 1571-5. doi: 10.17219/acem/104551.

31. Löffler D., Müller U., Scheuermann K., Friebe D., Gesing J., Bielitz J., Körner A. Serum irisin levels are regulated by acute strenuous exercise. The Journal of Clinical Endocrinology & Metabolism. 2015. 100 (4). 1289-99. doi: 10.1210/jc.2014-2932.